According to Zoetis's latest financial reports the company has $2.03 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | $2.03 B | -43% |
2022-12-31 | $3.57 B | 2.73% |
2021-12-31 | $3.48 B | -3.33% |
2020-12-31 | $3.60 B | 86.44% |
2019-12-31 | $1.93 B | 13.92% |
2018-12-31 | $1.69 B | 8.44% |
2017-12-31 | $1.56 B | 115.13% |
2016-12-31 | $0.72 B | -37% |
2015-12-31 | $1.15 B | 30.84% |
2014-12-31 | $0.88 B | 44.59% |
2013-12-31 | $0.61 B | 92.43% |
2012-12-31 | $0.31 B | 301.27% |
2011-12-31 | $79 M | 25.4% |
2010-12-31 | $63 M |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
Pfizer PFE | $12.69 B | 522.36% | ๐บ๐ธ USA |
Eli Lilly LLY | $2.92 B | 43.59% | ๐บ๐ธ USA |
Sanofi SNY | $9.92 B | 386.91% | ๐ซ๐ท France |
Merck MRK | $7.09 B | 247.87% | ๐บ๐ธ USA |
Phibro Animal Health
PAHC | $92.49 M | -95.46% | ๐บ๐ธ USA |
Kindred Biosciences
KIN | N/A | N/A | ๐บ๐ธ USA |
Heska Corporation
HSKA | $0.12 B | -93.86% | ๐บ๐ธ USA |